Shire's eye drug approved by US FDA
The US Food and Drug Administration has approved Shire's lifitegrast eye drops for treating signs and symptoms of dry eye disease.
Lifitegrast, to be sold under the Xiidra name, is expected to launch in the third quarter.
“An estimated 16m adults in the U.S. are diagnosed with dry eye disease. An often chronic ocular disease, dry eye is associated with inflammation that may eventually lead to damage to the surface of the eye. An eye care professional can diagnose dry eye disease based on signs and symptoms and determine management options, which could include the use of a prescription treatment,” Shire said.